Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) are a new generation of hepatitis C drug which unfortunately received a Food and Drug Administration (FDA) warning of causing symptomatic bradycardia, as well new concerns of causing hearing loss, also known as ototoxicty. Hepatitis C is an infectious disease affecting primarily the liver, caused by the hepatitis C virus (HCV). While the infection is often asymptomatic, chronic infection can lead to scarring of the liver and ultimately to cirrhosis (permanent liver damage).
We are currently investigating claims on behalf of injured users. Our firm has over 30 years of experience handling dangerous drugs cases.
If you or someone you know has side effects from Sovaldi or Harvoni the lawyers at Rheingold Giuffra Ruffo Plotkin & Hellman LLP are here to help you explore your legal options.
At Rheingold Giuffra Ruffo Plotkin & Hellman LLP, we take pride in helping people from New York and across the nation with their most critical legal problems. We are able to handle a wide range of dangerous drug liability claims, including those involving Sovaldi and Harvoni. The FDA announced in May 2015 that one side effect is bradycardia, which is an abnormally slow heartbeat. This has been reported with the drug in use in combination with certain other antivirals. Some of the symptoms are:
Patients have been reporting hearing loss with Sovaldi. They have also reported essential tremors, rheumatoid arthritis, ataxia and partial vision. The hearing loss has been sudden and resulted in a permanent loss of hearing. This may happen while on the drug or soon after. Some doctors may believe that reducing the dose may stop the conditions, but decreasing doses my not prevent the problems.
Our attorneys will work with you personally to determine the extent of your monetary damage and what legal remedies are at your disposal.